异基因造血细胞移植后晚期巨细胞病毒感染
结果显示CMV血症累积发生率与供受者CMV血清学状态相关,最高危D-R+组从第0-90天至271-360天依次为24.3、9、5和2.1。急性GVHD是主要风险因素,ptCY降低CMV感染风险,而来特莫韦预防与第+90天后CMV感染减少无关。
要点
- CMV血清学D-R+组CMV血症累积发生率从第0-90天的24.3%降至271-360天的2.1%。
- 急性GVHD是CMV感染的主要风险因素,ptCY与CMV感染风险降低相关。
- 来特莫韦预防未降低第+90天后CMV感染风险,可考虑第+180天后停用。
核心结论
- CMV感染风险在第+180天前仍具有临床意义,但受患者GVHD状态影响。
- 可考虑在第+180天后停用来特莫韦预防。
研究设计与样本
- 回顾性队列研究,纳入2015至2022年接受单次异基因造血细胞移植的2106例患者。
- 采用landmark分析,以死亡为竞争风险,按90天间隔计算第0至+360天CMV血症累积发生率。
- 对各间隔的基线及时间依赖协变量进行CMV血症和生存的回归分析。
主要发现
- CMV血症(≥500 IU CMV DNA/mL)累积发生率与供受者CMV血清学状态相关。
- 最高危D-R+组第0-90、91-180、181-270、271-360天累积发生率分别为24.3(95%CI 21.3-27.3)、9(95%CI 6.9-11.1)、5(95%CI 3.3-6.7)、2.1(95%CI 0.9-3.3)。
- 与CMV发生率相关的主要风险因素与急性GVHD相关。
- ptCY与CMV感染风险降低相关。
- 来特莫韦预防与第+90天后CMV感染减少无关。
关键数值与推荐
- CMV血症定义为≥500 IU CMV DNA/mL。
- D-R+组第0-90天CMV血症累积发生率为24.3(95%CI 21.3-27.3)。
- D-R+组第91-180天CMV血症累积发生率为9(95%CI 6.9-11.1)。
- D-R+组第181-270天CMV血症累积发生率为5(95%CI 3.3-6.7)。
- D-R+组第271-360天CMV血症累积发生率为2.1(95%CI 0.9-3.3)。
临床怎么用
- 对于D-R+等高危CMV血清学状态患者,应关注第+180天前的CMV感染风险。
- GVHD状态影响CMV感染风险,需结合GVHD情况调整CMV监测策略。
- 来特莫韦预防可考虑在第+180天后停用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. We studied the incidence, risk factors for, and outcomes of CMV infection after Day + 90 of allogeneic hematopoietic cell transplant (alloHCT). The patient cohort consisted of 2106 alloHCT patients treated from 2015 to 2022 with a single alloHCT. Fifty-seven percent of patients received ptCY. Forty-three percent of patients received letermovir. We performed landmark analysis of the cumulative incidence of CMV-emia with the competing risk of death from Day + 0 to +360 in 90-day intervals. Regression analyses of baseline and time-dependent covariates for CMV-emia and survival were performed for each interval. The cumulative incidence of CMV-emia (≥ 500 IU CMV DNA/mL) was associated with donor/recipient CMV serostatus. In the highest risk CMV serostatus donor negative and recipient positive (D-R+) group, the cumulative incidence was 24.3 (95% confidence interval [CI] 21.3-27.3), 9 (95% CI: 6.9-11.1), 5 (95% CI: 3.3-6.7), and 2.1 (95% CI: 0.9-3.3) from Day 0 to 90, 91 to 180, 181 to 270, and 271 to 360, respectively. The primary risk factors associated with CMV incidence were related to acute GVHD. PtCY was associated with a decreased risk of CMV infection. Letermovir prophylaxis did not associate with decreased CMV infection after Day + 90. In conclusion, the risk of CMV infection remains clinically significant until Day + 180, although this is affected by the GVHD status of the patient. Discontinuation of letermovir may be considered after Day + 180.
引用
- Chen GL, Bassett R, Mehta RS, et al. Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant. Am J Hematol. 2026. PMID: 42128671. doi:10.1002/ajh.70347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。